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ABSTRACT
The majority of cancers arise from malignant epithe-
lial cells. We report the design of synthetic oligo-
nucleotides (aptamers) that are only internalized
by epithelial cancer cells and can be precisely acti-
vated by light to kill such cells. Specifically, photo-
toxic DNA aptamers were selected to bind to unique
short O-glycan-peptide signatures on the surface
of breast, colon, lung, ovarian and pancreatic
cancer cells. These surface antigens are not present
on normal epithelial cells but are internalized and
routed through endosomal and Golgi compartments
by cancer cells, thus providing a focused mecha-
nism for their intracellular delivery. When modified
at their 5’ end with the photodynamic therapy agent
chlorin e6 and delivered to epithelial cancer cells,
these aptamers exhibited a remarkable enhance-
ment (>500-fold increase) in toxicity upon light acti-
vation, compared to the drug alone and were
not cytotoxic towards cell types lacking such
O-glycan-peptide markers. Our findings suggest
that these synthetic oligonucleotide aptamers
can serve as delivery vehicles in precisely routing
cytotoxic cargoes to and into epithelial cancer cells.
INTRODUCTION
Oligonucleotides cannot traverse cell membranes, a
feature that restricts their therapeutic potential either as
modulators of intracellular cell functions or as carriers
of therapeutic agents. However, short, single-stranded
RNA or DNA oligonucleotides known as aptamers (1,2)
have been shown to adopt distinct 3D structures comple-
mentary to a given molecular target. They are derived
from an initial combinatorial pool of random oligonucleo-
tide sequences using an in vitro selection approach termed
SELEX (Systematic Evolution of Ligands by Exponential
Enrichment (3,4). By judiciously selecting cell surface
structures as targets for aptamer searches, one can
derive aptamers that can speciﬁcally recognize internalized
surface markers (portals) and thus be imported into
cells. A case in point is the use of RNA aptamers recog-
nizing the human prostate antigen PSMA, to deliver
siRNA molecules into such cells (5). Membrane-
associated glycoforms of mucin glycoproteins represent
an important class of tumor surface markers that are
uniquely and abundantly expressed on a broad range of
epithelial cancer cells (breast, ovary, colon, pancreas,
lung and prostate) (6,7). These markers are also rapidly
recycled through intracellular compartments (endosomes,
Golgi) (8–11), and thus can serve as entry portals for
aptamers. Mucins typically harbour variable numbers of
peptide tandem repeats (VNTR) rich in serine, threonine
and proline residues (12) where serines and threonines
are post-translationally modiﬁed with O-linked oligosac-
charides (O-glycans). Carbohydrate chains account for
more than 50% of their mass (12). The aberrant glyco-
sylation of mucins has been shown to promote a meta-
static phenotype (13–15). Shortened carbohydrate chains
and peptide epitopes are revealed as a consequence of
incomplete O-glycosylation events occurring in these
cells. Monoclonal antibodies raised against tumour-
associated forms of MUC1 commonly recognize part
of the mucin exposed peptide backbone or the Tn
(GalNAc) and T (Galb1-3GalNAc) antigens O-linked to
the peptide tandem repeat (16). We have recently
generated a peptide corresponding to ﬁve consecutive
mucin MUC1 tandem repeats (MUC1-5TR) and bio-
synthetically introduced GalNAc sugars (MUC1-5TR-
GalNAc; Tn antigens) within its structure (17) with a
view to deriving short, single-strand DNA aptamers dis-
playing a more focused speciﬁcity for these tumour anti-
gens than monoclonal antibodies. We now report that
these 25-base long synthetic DNA aptamers are eﬃciently
internalized by epithelial cancer cells and can be used as
delivery vehicles to speciﬁcally route pro-drug cargoes
such as photodynamic therapy (PDT) agents into such
cells to kill them.
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Reagents for SELEX screens
We initially engineered mimics of known mucin MUC1
determinants (17) on cancer cells namely a recombinant
deglycosylated peptide representing ﬁve MUC1 tandem
repeats (MUC1-5TR) and its O-glycosylated form con-
taining 15 GalNAc sugars (Tn antigens, MUC1-5TR-
GalNAc) to serve as targets in selecting DNA aptamers.
Brieﬂy, a synthetic gene coding for ﬁve copies of the
MUC1 tandem repeat and a N-terminal hexahistidine
metal aﬃnity tag (MUC1-5TR) was inserted into the
pET-15b expression vector (Novagen, Madison, WI).
The resulting construct was used to transform competent
Escherichia coli BL21 (DE3) cells (Novagen) and the
expression of MUC1-5TR induced with isopropyl
b-D-thiogalactopyranoside (IPTG). MUC1-5TR was puri-
ﬁed by nickel aﬃnity chromatography under denaturing
conditions. The sequence of the puriﬁed MUC1-5TR was
conﬁrmed by mass spectrometry and the peptide was
stored at  208C until use. MUC1-5TR was enzymatically
modiﬁed with up to 15 GalNAc sugars (Tn antigen) using
a recombinant secreted form of the human ppGalNAc-T1
expressed in Pichia pastoris (17). Unglycosylated MUC1-
5TR or its Tn-labelled form (3mg) were separately
immobilized unto1mm HiTrap Chelating HP columns
(GE Healthcare, Baie d’Urfe ´ , Que ´ bec). The target
loaded matrices were subsequently used for aptamer
selection. In the case of N-acetylgalactosamine being
used as a target, plates covalently modiﬁed with this
sugar were purchased from EMD Biosciences
(Mississauga, Ontario). Brieﬂy, GalNac determinants
were directly coupled using an amide linkage to wells
of a 96-well polystyrene plate via a 16–18 atom ﬂexible
spacer, providing a homogeneous presentation of the
target to putative DNA aptamers emerging as strong
ligands. Plates were kept at  208C for the duration of
the experiment, except during ssDNA library incubation
times. In vitro selection strategies based on SELEX
approach were developed to identify aptamers that bind
to all three targets under physiological conditions
(150mM NaCl, 5mM MgCl2, pH 7.4, 378C. (Figure 1a,
Table 1). The selection of MUC1 DNA aptamers is
described in Supplementary Data section 1 and in ref.
(18). Selected aptamer pools were ampliﬁed by asymmetric
PCR (aPCR) using an excess of forward primer (1000 )
and limiting the amount of reverse primer (1 ) to favour
the production of sense (50 to 30) single-stranded DNA
products (DNA aptamers) (19).
All subsequent oligonucleotides were purchased from
Midland Certiﬁed Reagent Co (Midland, Texas, USA)
either as unmodiﬁed aptamers or labelled at their 50
amino end with biotin, chlorin e6 or Rhodamine101.
Electrophoretic mobility shiftassays (EMSA)
The association of DNA aptamers recognizing MUC1
peptide constructs with their respective target was con-
ﬁrmed by a shift in their electrophoretic mobility in
a 6% polyacrylamide pre-cast DNA retardation gel
(Invitrogen, Burlington, Canada) upon complexation
with their target. Qualitative EMSA was performed
using a binding reaction mixture (20ml) composed of
100mM NaCl, 5mM MgCl2, 100mM KCl, 1mM dithio-
threitol, 5% glycerol, a protein target (5ml, 1mg/ml) and
a
32P-labelled DNA aptamer. The mixture was incubated
for 30min at room temperature and electrophoretically
resolved at a constant voltage of 150V for 2h at room
temperature. The running buﬀer was 1/2 TBE (0.045M
Tris borate, pH 8,1mM EDTA). The gel was subse-
quently dried and exposed to ﬁlm.
Surface plasmonresonance (SPR) measurements
All SPR-binding measurements were recorded on a
BIAcore 3000 instrument using nickel NTA sensor chips
(CM5 chip; GE Healthcare, Baie d’Urfe ´ , Que ´ bec). The
MUC1 peptide antigens carry a hexa histidine tag and
were directly immobilized onto NTA chips by dissolving
each antigen in 10mM sodium acetate (pH 5.2) and inject-
ing them onto a chip at a concentration of 500mg/ml.
The chips were equilibrated in a binding buﬀer (100mM
NaCl, 5mM MgCl2 (pH 7.4) that also served as the
running buﬀer. The ﬂow rate was 5ml/min. Calculations
of kinetic parameters from SPR measurements are pre-
sented in Supplementary Data section 2.
The DNA aptamers were refolded in the binding buﬀer
for the dose-dependent binding assays and injected over
the ﬂow cells. The surfaces were regenerated between
injections using two 5ml injections of 10mM NaOH,
followed by a 10-min wash step with the running buﬀer.
The association and dissociation rate constants for
aptamer–peptide and aptamer–sugar complexes were
determined using a non-linear regression analysis for the
initial parts of association and dissociation phases of
the sensograms. (7.5 Origin Pro software; MicroCal).
Flow cytometryand internalization studies
Rhodamine-labelled aptamers (200pmol) were incubated
with 10
5 cells of either MCF-7, T47D, PANC-1 or CHO
cells at 378C for 30min to determine the level of MUC1
expression on their surface. Cells were trypsinized, washed
three times with PBS and counted using a hemocytometer.
The cells were resuspended in 500ml of PBS and 4% FBS
and incubated with either 200pmol of a rhodamine-
labelled aptamer or with the mAb OncM27 (20) for
30min at 378C. Cells were subsequently washed three
times with PBS and the antibody-stained cells were further
incubated with 1:1500 dilution of FITC-labelled anti-
mouse antibody (BD Biosciences, Franklin Lakes, NJ)
in PBS. After a 30min incubation period, cells were
washed three times with PBS and analysed by ﬂow cyto-
metry (FACScan; BD Biosciences, Franklin Lakes, NJ).
Internalization studies were carried out as described
above, with the added modiﬁcations that all aptamers
and mAb OncM27 were incubated at 378Co ra t4 8C (on
ice) for the period of time ranging from 30min to 6h.
Confocal microscopy
MCF-7, T47D, PANC-1 or CHO cells were grown in
duplicate wells of four-well chambered coverglass tissue
culture microscopy plates (NUNC). Cell medium was
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three times with PBS. Rhodamine-labelled aptamers or
the mAb OncM27 were dissolved in PBS and added to
the wells at concentrations ranging from 0.05pmol/mlt o
1pmol/ml. Plates were incubated for 30min at 378C. Wells
were washed three times with PBS and treated with 2ml
per 1000ml of a 2% (w/v) BSA solution prepared in PBS.
In the case of the mAb OncM27, a second labelling step
was necessary with a FITC-labelled anti-mouse antibody
(Pharmingen, Becton Dickinson) for 30min at 378C. Cells
were washed three times and kept in 20mM Hepes buﬀer
prior to microscopy. Either 100ml of PBS (control) or
100ml of a 0.25pmol/ml solution of a ﬂuorescently labelled
aptamer in PBS were dispensed in each well. The DNA
aptamers were allowed to complex with MUC1 targets
present on the surface of cells for 30min. Individual
wells were washed three times with 1ml of PBS.
Adherent cells in wells were visualized using a Two-
Photon Zeiss LSM 510 META NLO microscope, HeNe
Laser—(543nm) HeNe Laser—(633nm), C-Apo 40 /
1.2NA lens, at 40 1.6 10 magniﬁcation, and analysed
with LSM150 image browser software. Phase-contrast
and confocal images (2mm thickness) of viable cells were
taken after the 30min incubation period.
Photodynamic treatment
The PDT agent chlorin e6 was introduced post-synthesis
at the 50 amino group of DNA aptamers Brieﬂy, a single
carboxylic acid of chlorin e6 was coupled with EDC
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Figure 1. (a) Schematic representation of the selection process leading to the discovery of epithelial tumour-speciﬁc DNA aptamers. Single-strand
DNA oligonucleotides were derived using the SELEX (systematic evolution of ligands by exponential enrichment) approach (4). Speciﬁcally, a pool
of ssDNAs displaying a 25nt random region was incubated with either His-tagged MUC1-5TR peptide or its GalNAc-modiﬁed variant (Tn antigen)
bound to nickel-NTA beads or with N-acetylgalactosamine immobilized in wells of a 96-well plate. Bound oligonucleotides were recovered using
a high salt step, desalted and ampliﬁed by asymmetric PCR before a new cycle of selection. After 10 rounds of selection, each DNA aptamer pool
was cloned and sequenced. Individual aptamers were synthesized and further analysed to assess their speciﬁcity. (b) Binding speciﬁcity of DNA
aptamers to their respective target. The association of 11 distinct DNA aptamers (Table 1) recognizing MUC1 peptide constructs (MUC1-5TR, Tn
antigen) as well as the carbohydrate N-acetylgalactosamine (GalNAc) with their respective target was further conﬁrmed using an electrophoretic
mobility shift assay (EMSA). Aptamers were incubated with their target for 30min and resolved on a 6% polyacrylamide DNA retardation gel.
DNA–peptide complexes were observed when aptamers 5TR1, 5TR2, 5TR3 and 5TR4 were mixed with their target namely unglycosylated MUC1-
5TR. Similarly, complexes were observed when aptamers 5TRG1, 5TRG2, 5TRG3, 5TRG4, GalNAc1, GalNAc2 and GalNAc3 were added to the
peptide MUC1-5TR-GalNAc (Tn antigen). Individual DNA aptamers derived from diﬀerent glycosylated targets (Tn antigen versus GalNAc alone)
displayed distinct band shifts with the MUC1-5TR-GalNAc peptide (Tn antigen). The higher mass species observed for all GalNAc-speciﬁc aptamers
bound to glycosylated MUC1 (MUC1-5TR-GalNAc) reﬂect the higher molar ratio of bound aptamers (GalNAc1, GalNAc2 and GalNAc3)
recognizing up to 15 GalNAc groups per MUC1-5TR-GalNAc peptide (17) while aptamers recognizing features from both peptide and sugar
components (5TRG1, 5TRG2, 5TRG3, 5TRG4) yielded distinct band migration proﬁles.
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solved in potassium phosphate, pH 7.0) using a 1:3:3
molar ratio of aptamer to chlorin e6 and EDC. The
coupling mixtures were left to react overnight at 608Ci n
the dark. The conjugates were then loaded on a C18
column equilibrated in 0.1M sodium acetate, pH 7.0
and eluted with a gradient of the same buﬀer going
from 0% to 40% AcN. Aliquots of 5 10
3 cells of either
human cancer cells (T47D, MCF-7, PANC-1, BxPC3,
A549, MGH13, OVCAR-3, HT-29, U87MG), CHO cells
or normal human primary mammary epithelial cells
(HMEC) (Clonetics; Lonza, Basel, Switzerland) sus-
pended in 200ml growth medium were seeded into wells
of blackened 96-well plates with clear bottoms (Corning
Costar Corp., Cambridge, MA) and cultured for 6h at
378C in the presence of 5% CO2. Cells were treated with
PBS or increasing concentrations of either chlorin e6 or
chlorin e6-aptamers followed by light activation treat-
ments. Control samples were also prepared and kept
from light. Wells were irradiated with 664nm light from
above using an optic ﬁbre coupled to a dye laser source
(Spectra Physics model 375B), applying a radiant expo-
sure of 12J/cm
2 at ﬂuency rate of 20–30mW/cm
2. Once
irradiated, cells were incubated with fresh growth medium
for an additional 48h at 378C in the dark. Cell viability
was assessed using a methyltetrazolium salt (MTT) colori-
metric assay (21). Speciﬁcally, 24h following aptamer
or chlorin e6 treatment and light activation, cells were
incubated with methyl-tetrazolyl tetrazolium (2mg/ml)
for 4h at 378C. The medium was then replaced with
100ml dimethylsulfoxide and the plates shaken for 5min.
Absorbance was read at the 570nm and dose-response
curves were plotted using GraphPad Prism software for
experiments performed in triplicate.
Photoinduced oxidative burst
MCF-7 and T47D cells (2 10
4 cells) were seeded onto
a Lab-Tek coverglass 2 chamber slide in 1ml of growth
medium containing 0.01mM chlorin e6-aptamers and
incubated (378C, 5% CO2) for 1h in the dark and then
washed with PBS (three times) under strictly subdued light
conditions. Cells were exposed for 25min at 378Ci n
medium containing 5mM of 5 (and 6)-chloromethyl-20,70-
dichlorodihydroﬂuorescein diacetate (CM-H2 DFDA)
Slides remained at room temperature in the dark until
analysed by confocal microscopy. Single cells were visua-
lized before and after light activation of chlorin e6 or
chlorin e6 aptamers. Reactive oxygen species (ROS) sig-
nals were recorded using a scanning confocal imaging
system (Argon-ion laser; 488/514.5nm; MRC 600, Bio-
Rad Laboratories Ltd, Ont., Canada). Signals were
viewed through a 63 /0.55 Nikon water-immersible
objective lens. Chlorin e6 was activated using a helium
cadmium (HeCd) laser (omNichrome series 56). The ﬂuor-
escence signal from CM-H2 DFDA was simultaneously
recorded using a green ﬁlter, allowing for a direct intra-
cellular visualization of ﬂuorescent signals over a 10s
period.
RESULTS
Aptamerselection and characterization
We recently engineered mimics of known mucin MUC1
determinants on cancer cells namely a recombinant
deglycosylated peptide representing ﬁve MUC1 tandem
repeats (MUC1-5TR) and its O-glycosylated form con-
taining 15 GalNAc sugars (Tn antigens; MUC1-5TR-
GalNAc) (17) to serve as targets in selecting DNA
aptamers (Figure 1). In addition, an immobilized form
of N-acetylgalactosamine (GalNAc) was used as a target
to deﬁne DNA aptamers that only recognize the carbo-
hydrate component of MUC1-5TR-GalNAc. Eleven apta-
mers displaying nanomolar-binding constants for their
respective targets are presented in Tables 1 and 2. A com-
parison of calculated Kd values for all aptamers binding
to MUC1 peptides lacking or not GalNAc sugars
(Table S1) suggests that they can readily diﬀerentiate
peptide targets harbouring or not GalNAc residues.
Table 1. List of nucleotide sequences deﬁning the speciﬁcity of each DNA aptamer
50 >GGGAGACAAGAATAAACGCTCAA <30 (Forward primer)
50 >GCCTGTTGTGAGCCTCCTGTCGAA<30 (Reverse primer) 50
50GAGACAAGAATAAACGCTCAA-(N25)-TTCGACAGGAGGCTCACAACAGGC 03
5TR1 GAAGTGAAAATGACAGAACACAACA 25nt
5TR2 GGCTATAGCACATGGGTAAAACGAC 25nt
5TR3 CAAACAATCAAACAGCAGTGGGGTG 25nt
5TR4 TACTGCATGCACACCACTTCAACTA 25nt
5TRG1 GGGTTATATTACTCGGCCGGTGTAA 25nt
5TRG2 GGCTATAGCACATGGGTAAAACGAC 25nt
5TRG3 GGCGTACGGTAGGCGGGGTCAACTG 25nt
5TRG4 GCTGGGTAAATAGATGATTCCCGGC 25nt
GalNac1 AGACTTAGGTGGATGTAGGATCCTT 25nt
GalNac2 CTCCGATCCACTAGTAACGGCCGCC 25nt
GalNac3 AAGGGATGACAGGATACGCCAAGCT 25nt
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MUC1 glycoforms
DNA aptamers displaying the highest aﬃnity constant for
their respective target, namely 5TR1, 5TRG2 and
GalNAc3 (Table 2), were labelled at their 50 end with
rhodamine and their binding to cells expressing MUC1
glycoforms analysed by ﬂow cytometry and by two-
photon confocal microscopy (Figure 2). The monoclonal
antibody OncM27 (20) recognizes the peptide epitope
TRP within the MUC1 tandem repeat (16) and was used
to conﬁrm the expression of MUC1 mucin on all cell
lines tested (see Figure S1, Supplementary Data). The
ﬂow cytometric proﬁles presented in Figure 2, indicate
that all three ﬂuorescent aptamers as well as the mAb
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Figure 2. (a) Selective binding of DNA aptamers to tumour-speciﬁc MUC1 determinants on cancer cells. The cancer cell lines MCF-7 (MUC1
+
human breast cancer), T47D (MUC1
+ human breast cancer), PANC-1 (MUC1
+ human pancreatic cancer) as well as CHO cells (MUC1
  Chinese
hamster ovary; negative control) were stained with rhodamine-labelled DNA aptamers and analysed by ﬂow cytometry. Cell-type speciﬁc binding was
observed for aptamers 5TR1 (blue), 5TRG2 (pink) and GalNAc3 (green). The background autoﬂuorescence of unstained cells (black line) is shown
for each cell line. Cells were also stained with the mAb OncM27 (recognizes the mucin MUC1 tandem repeat; Supplementary Figure S1) to conﬁrm
the expression of MUC1 determinants on cancer cells. (b) Speciﬁc staining of MUC1 and Tn antigen tumour markers on cancer cells as monitored by
confocal microscopy. MCF-7, T47D, PANC-1 and CHO (negative control) cells were stained with three representative rhodamine-labelled MUC1
aptamers (red), namely 5TR1 binding to the unglycosylated MUC1 tandem repeat core, 5TRG2 recognizing peptide-GalNAc (Tn antigen) determi-
nants and the aptamer GalNAc3 staining terminal GalNAc groups. Confocal images of viable cells recorded at 378C were taken 30min post
incubation. Composite images were created to reveal the routing of rhodamine-aptamers to endosomal and lysosomal compartments
(Lysotracker-stained (green) organelles). As a control, cells were also stained with the mAb OncM27 (recognizes the mucin MUC1 tandem
repeat; Figure S1) and confocal images recorded to conﬁrm the internalization of MUC1 and Tn antigen markers.
Table 2. Kinetic parameters and calculated Kd values for DNA
aptamers
Aptamer SELEX target ka (M
 1s
 1)
a kd (s
 1)
a Kd (nM)
5TR1 MUC1-5TR 1.22 10
7 0.0026 21.0
5TR2 MUC1-5TR 1.48 10
7 0.01268 85.2
5TR3 MUC1-5TR 0.43 10
7 0.00358 83.0
5TR4 MUC1-5TR 0.45 10
7 0.00311 69.0
5TRG1 Tn antigen 1.33 10
7 0.00398 25.1
5TRG2 Tn antigen 1.02 10
7 0.0186 18.6
5TRG3 Tn antigen 0.92 10
7 0.00252 27.2
5TRG4 Tn antigen 0.91 10
7 0.00314 34.4
GalNAc1 N-Acetylgalactosamine 1.33 10
7 0.0801 59.8
GalNAc2 N-Acetylgalactosamine 2.02 10
7 0.1199 58.3
GalNAc3 N-Acetylgalactosamine 0.21 10
7 0.00098 47.3
a 
2>0.981.
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MUC1-expressing epithelial cancer cell lines [MCF-7
(human breast cancer), T47D (human breast cancer) and
PANC-1 (human pancreatic cancer)], while the same
probes fail to bind to CHO cells (MUC1
  cells). The
two-photon confocal images presented in Figure 2 further
illustrate that the chosen aptamers are able to recognize
either the MUC1 peptide backbone or GalNAc deter-
minants associated with the mucin MUC1 tandem
repeat. As expected, no cell staining was observed for
MUC1
  CHO cells.
Aptamers asselective delivery vehicles into epithelial
cancer cells
The anionic character of oligonucleotides does not
favour their spontaneous entry into cells. However,
epithelial cells recycle underglycosylated forms of mucin
MUC1 from their surface to the trans-Golgi network to
further modify their glycan structure. MUC1 has been
shown to be recycled through endosomal/lysosomal and
the trans-Golgi network from the apical surface several
times, a process that is accompanied by further sialylation
of the O-glycans (9–11,22). To determine if our aptamers
could be transported into cells by virtue of their associa-
tion with MUC1 targets, we measured the time-dependent
cellular uptake of rhodamine-labelled aptamers 5TR1,
5TRG2 and GalNAc3 by ﬂow cytometry at 48C and
378C as well as in the presence of monodansyl cadaverine,
an inhibitor of coated pit formation and receptor-
mediated endocytosis (Figure 3) (23–25). As predicted,
the aptamers 5TR1, 5TRG2 and GalNAc3 were rapidly
endocytosed by MUC1
+ cells at 378C but not at 48Co rb y
Figure 3. Time-dependent internalization of rhodamine-labelled aptamers into MCF-7, T47D, PANC-1 and CHO cells as measured by ﬂow
cytometry. Incubations were performed at 48C (ﬁlled triangle), 378C (ﬁlled circle) or in the presence of monodansyl cadaverine (ﬁlled square;
378C) for up to 6h. In all panels, curves represent the time-dependent changes in relative mean ﬂuorescence intensities for cells exposed to 5TR1
aptamer (a), 5TRG2 aptamer (b), GalNAc3 aptamer (c), or an irrelevant 25 base-long DNA aptamer composed of GATC repeats (d). All data points
represent the average relative mean ﬂuorescence intensities derived from experiments performed in triplicate.
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  cells (Figure 3). Their cellular uptake was signiﬁ-
cantly inhibited by monodansylcadaverine suggesting
that their entry into MUC1
+ cells occurred by receptor-
mediated endocytosis (Figure 3). A control irrelevant
aptamer did not enter either MUC1
+ or MUC1
  cells
(Figure 3d). Thus, the evaluated DNA aptamers remained
membrane-impermeant unless they were able to associate
with an internalized surface marker. In terms of cellular
localization, confocal microscopy images indicate that
internalized DNA aptamers migrate through endosomal,
lysosomal as well as through Golgi compartments and
potentially to the cytosol of epithelial cancer cells
but not to the ER lumen or nucleus of MUC1
+ cells
(Figures 2 and 4).
Light-activated aptamers selectively kill epithelial
cancer cells
PDT drugs are activated by light to produce cytotoxic
singlet oxygen species. Their eﬀectiveness as therapeutic
agents is dependent on their cellular delivery. Since,
aptamers 5TR1, 5TRG2 and GalNAc3 are selectively
delivered into epithelial cancer cells, we introduced at
their 50 end, the heme-like PDT agent chlorin e6 (Ce6).
Our aim was to demonstrate that, by virtue of their
guided cellular targeting and intracellular routing, PDT-
aptamers can target and kill MUC1 presenting cancer cells
at much lower doses of chlorin e6 than the free drug itself.
As presented in Figure 5, chlorin e6-aptamers directed at
eight MUC1
+ epithelial cancer cell lines (T47D, MCF-7,
PANC-1, BxPC3, A549, MGH13, OVCAR-3, HT-29)
were >500 times more toxic (on a molar basis) upon
light activation than the free drug chlorin e6. More impor-
tantly, these same aptamers were not toxic towards
MUC
  cells (CHO cells, U87MG cells) or MUC1
+
normal human primary mammary epithelial cells display-
ing fully glycosylated MUC1 mucin (Figure 5). Finally,
DNA aptamers lacking the chlorin e6 group or a chlorin
e6-aptamer harbouring an irrelevant nucleotide sequence
were not able to kill either MUC1
+ or MUC1
  cells
(Figure 5). The dramatic enhancement in cellular toxicity
with chlorin e6-aptamers upon light treatment can be
rationalized by the production and rapid cellular re-dis-
tribution of toxic singlet oxygen species throughout cancer
cells (oxidative burst). This phenomenon was visualized in
cells as the result of capturing the emission of light by
chloromethyl-20,70-dichlorodihydroﬂuorescein diacetate/
AcrO upon reaction with the generated
1O2 species
(Figure 6a).
DISCUSSION
The directed delivery of membrane-impermeant thera-
peutic oligonucleotides into diseased cells represents an
essential criterion for improving their safety, cost and
eﬃcacy in in vivo settings. These important parameters
must be addressed in devising targeted cancer therapies
that can home on cancer cells while sparing normal
tissues. We present evidence that internalized surface
markers such as underglycosylated mucin MUC1 antigens
can act as highly selective portals in importing oligonu-
cleotides such as DNA aptamers into a broad range of
epithelial cancer cells (breast, ovary, prostate, pancreas,
colon and lung). When aptamers directed at the MUC1
ER Tracker  Green  Golgi Bodipy FL
(a)
(b) (c)
(d)
(e) (f)
Figure 4. The DNA aptamer 5TRG2 is routed through Golgi compartments but not the ER lumen or nucleus of MUC1
+ cells. Viable T47D cells
were stained with both ER Tracker selective for endoplasmic reticulum (green; c) and Golgi Bodipy FL selective for the Golgi complex (green; f) dyes
as well as with rhodamine-labelled aptamer 5TRG2 (red; b and e). Composite images (a and d) derived from two-photon confocal images suggest
that the aptamer 5TRG2 only reaches Golgi compartments in T47D breast cancer cells (white arrows).
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Figure 5. DNA aptamers labelled with the photodynamic agent chlorin e6 selectively kill epithelial cancer cells. Cell viability curves were constructed
for eight MUC1
+ human cancer cells (human breast cancer cell lines T47D and MCF-7, human pancreatic cancer cell lines PANC-1 and BxPC3,
human lung cancer cell lines A549 and MGH13, human ovarian cancer cell line OVCAR-3, colon cancer cell line HT-29), two MUC1
  cell lines
(Chinese Hamster Ovary cells [CHO], human malignant glioma cell line U87MG) as well as fully glycosylated MUC1
+ normal human mammary
epithelial cells (HMEC). Cells were incubated in the presence of increasing concentrations of chlorin e6 alone (x), or either chlorin e6-labelled Ce6-
5TR1 aptamer (open square), Ce6-5TRG2 aptamer (open triangle), Ce6-GalNAc3 aptamer (open circle), unmodiﬁed 5TR1 aptamer (ﬁlled square),
5TRG2 aptamer (ﬁlled triangle), GalNAc3 aptamer (ﬁlled circle), or a Ce6-irrelevant aptamer (open diamond). Cell viability was determined for cells
exposed (full graph) or not (captioned graph within each graph) to photoirradiation and reported as the percentage surviving cells measured in a
MTT assay. The term concentration refers to the molar concentration of chlorin e6 either as a free drug or conjugated to aptamers. The irrelevant
DNA aptamer used was a 25 base-long oligonucleotide composed of GATC repeats and labelled with chlorin e6 and was shown not to be toxic to
MUC1
  and MUC1
+ cells.
Nucleic Acids Research,2009, Vol. 37,No. 3 873peptide or its related Tn antigens were armed to carry a
cytotoxic cargo such as the light-activated PDT drug,
chlorin e6, their ability to kill epithelial cells was enhanced
by several orders of magnitude upon light exposure in
comparison to the free drug alone (Figure 5). This
phenomenom was demonstrated for eight human
MUC1
+ cancer cell lines (T47D, MCF-7, PANC-1,
BxPC3, A549, MGH13, OVCAR-3, HT-29) representing
ﬁve classes of epithelial cancer cells (breast, pancreas,
lung, ovaries, colon). More importantly, the inability of
anionic oligonucleotides to spontaneously enter cells
resulted in no observable non-speciﬁc toxicity towards
MUC1
  cells (CHO, U87MG) or even to MUC1
+
normal human primary mammary epithelial cells display-
ing fully glycosylated MUC1 mucins (Figure 5). Our ﬁnd-
ings suggest that known cytotoxic drugs, prodrugs as well
as oligonucleotide-based cargoes such as siRNAs, PNAs,
ribozymes or antisense oligonucleotides could be coupled
to deglycosylated mucin- and Tn antigen-directed apta-
mers in order to target and deliver them to a broad
range of epithelial cancers. The recent design of chimeras
involving RNA aptamers against the prostate-speciﬁc
membrane antigen (PSMA) linked to siRNAs, supports
our claim that aptamers can be used as directed delivery
agents (5). However, siRNAs do require a very precise
delivery since they are known to non-speciﬁcally activate
toll-like receptors leading to interferon production (26,27).
In addition and as in the case of other cytotoxic agents,
siRNAs may potentially kill non-targeted cell types if their
cellular action triggers apoptotic mechanisms, a
challenge that further emphasize the need for a focused
delivery strategy. For this reason, we have employed a
prodrug strategy illustrated in Figure 6b, where the PDT
agent chlorin e6 is coupled to DNA aptamers, delivered
into targeted cancer cells and activated by light to generate
damaging singlet oxygen species and cell death.
Mechanistically, DNA aptamers directed at the MUC1
tandem repeat or its Tn antigen were rapidly internalized
by receptor-mediated endocytosis (Figures 2 and 3), a
result that correlates with Hughey and her coworkers
(28,29) who showed that underglycosylated MUC1
mucins are recycled by clathrin-mediated endocytosis
and traﬃcked through vesicular compartments including
lysosomes. Our data suggest that such aptamers are
routed through endosomal, lysosomal and Golgi compart-
ments (Figures 2 and 4) but not to the nucleus of cells
(Figure 4). Singlet oxygen species however do diﬀuse to
all cellular locations (Figure 6a) implying that aptamer
delivery to the nucleus or cytosol is not a necessary
prerequisite for eﬃcient toxicity to occur. One require-
ment may thus be that the toxic agent (either singlet
oxygen, radiation or a diﬀusible drug) be able to relocate
across cellular compartments.
Monoclonal antibodies to the extracellular portion of
the MUC1 peptide domain and its Tn antigen are
currently being evaluated as potential imaging and
therapeutic agents (30,31). However, aptamers represent
smaller, simpler, non-antigenic alternatives to antibodies
and as presented in this study, display remarkably high
speciﬁcity and aﬃnity (Kd’s in the nanomolar range) for
unique GalNAc-peptide structures speciﬁcally found on
epithelial cancer cells. These ﬁndings suggest that the
bivalent or multivalent nature of antibodies and lectins
typically needed to recognize carbohydrate determinants
are not required for DNA aptamers targeting GalNAc-
containing mucin markers (Table 2). In addition, methods
to chemically stabilize and alter the pharmacokinetics
of aptamers have already led to the FDA approval of
Macugen, a pegylated RNA aptamer directed at the vas-
cular endothelial growth factor (VEGF) therapy and
shown to help reduce the risk of vision loss in patients
with neovascular age-related macular degeneration (32).
Finally, PDT is a safe, non-radioactive treatment
modality that is well suited to treating a broad range of
topical and luminal tissues using endoscopic light sources
(via interstitial, bronchoscopic, colonoscopic or intra-
peritoneal procedures). Applications of PDT for treating
patients with breast (33), prostate (34), lung (35) and
oesophageal (36,37) cancers are now well documented.
Nevertheless, there is a strong need to speciﬁcally
deliver sensitizers to diseased cells in order to minimize
damage caused to healthy tissues upon illumination (38).
The phototoxic aptamers described in this study would
directly address the issue of PDT toxicity to normal tissues
since malignant cells derived from such tissues typically
express unique mucin and Tn antigen surface signatures,
0 sec 2 sec 5 sec 10 sec
(a)
(b)
Figure 6. (a) Light activation of chlorin e6-labelled aptamer 5TRG2
internalized by T47D cells produces toxic oxygen species observed
across all cellular compartments. Visualization by two-photon confocal
microscopy imaging of ROS production in T47D cells treated with
Ce6-5TRG2 and the 5-(and-6-)-chloromethyl-20,70-dichlorodihydro-
ﬂourescein diacetate acetyl ester (CM-H2DCFDA) as demonstrated
by the appearance and fading of yellow colour over a 10s photoirra-
diation interval. (b) Proposed mechanism of action of phototoxic DNA
aptamers directed at MUC1
+ epithelial cancer cell markers. Aptamers
(orange) bind to membrane-bound, underglycosylated MUC1 mucin
(red branched structures). These mucin structures are recycled from
the cell surface to the Golgi network where they are further glycosy-
lated before returning to the cell surface. PDT drugs coupled to such
aptamers and relocated into epithelial cancer cells are activated by light
to produce toxic
1O2 species resulting in selective cell death.
874 Nucleic Acids Research, 2009, Vol. 37, No. 3and would thus represent the only target of such PDT
aptamers.
In summary, highly expressed and aberrantly glyco-
sylated MUC1 determinants are found in greater than
90% of all primary and metastatic breast cancers (7,13)
as well as most epithelial carcinomas (7). This study high-
lights that targeting small phototoxic DNA aptamers
to underglycosylated determinants of MUC1 oﬀers great
potential in directing therapeutic agents to and into a
broad range of epithelial cancer cells.
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